<DOC>
	<DOCNO>NCT00847119</DOCNO>
	<brief_summary>The project objective evaluate efficacy neoadjuvant treatment bevacizumab , capecitabine radiotherapy , patient rectal adenocarcinoma resectable locally advanced ( stage T3 T4 ) , without presence ganglionar metastasis without distant metastasis .</brief_summary>
	<brief_title>Xeloda Bevacizumab Treat Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . The patient give write informed consent prior study related procedure 2 . Male female age 18 75 year 3 . ECOG performance status 0 1 4 . Histologically confirm diagnostic adenocarcinoma rectum &lt; 15 cm anal verge 5 . Clinical stage T3 , T4 with/without regional lymph node metastasis , without metastatic disease 6 . Disease evaluable image technique 7 . No tumour haemorrhage week prior start study treatment 8 . External derivation symptomatic occlusive tumour 9 . Not prior cancer treatment 10 . Adequate bone marrow , hepatic renal function , define : 1 . White blood cell ≥ 4 x 109 /l 2 . Absolute neutrophil count ≥ 1.5 x 109 /l 3 . Platelets ≥ 100 x 109 /l 4 . Haemoglobin ≥10 g/dl 5 . Bilirubin &lt; 1.25 x upper limit normal 6 . Aspartate transaminase alanine transaminase &lt; 2.5 x upper limit normal 7 . Serum creatinine ≤ 106 µmol/l 11 . Less 10 % weight loss 1 . Rectal cancer amenable resection 2 . Any malignancy active treat within past 5 year , exception situ carcinoma cervix nonmelanoma skin lesion adequately treat 3 . Pregnant breastfeed woman 4 . Women oh childbearing potential unless effective method contraception use 5 . No prior concurrent significant medical condition , include follow : Cerebrovascular disease ( include transient ischemic attack stroke ) within past year Cardiovascular disease , include follow : Myocardial infarction within past year Uncontrolled hypertension receive chronic medication Unstable angina New York Heart Association class IIIV congestive heart failure Serious cardiac arrhythmia require medication 6 . Major trauma within past 28 day 7 . Serious nonhealing wound , ulcer , bone fracture 8 . Evidence bleed diathesis coagulopathy 9 . No lack physical integrity upper gastrointestinal tract , malabsorption syndrome , inability take oral medication 10 . No evidence disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug 11 . No known dihydropyrimidine dehydrogenase deficiency 12 . Major surgery 4 week prior start study treatment 13 . No concurrent chronic , daily treatment aspirin ( &gt; 325 mg/day ) 14 . More 10 day since prior use fulldose oral parenteral anticoagulant therapeutic purpose 15 . No participation another clinical trial investigational drug within 30 day prior randomization study participation 16 . No medical history condition , opinion investigator , would preclude study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>rectum</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>capecitabine</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>locally</keyword>
	<keyword>advanced</keyword>
	<keyword>resectable</keyword>
	<keyword>resectable locally advanced adenocarcinoma rectum</keyword>
	<keyword>xeberecto</keyword>
</DOC>